This Article Full Text Full Text (PDF) Supplementary Data All Versions of this Article: 0008-5472.CAN-08-2250v1 69/6/2358    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Polson, A. G. Articles by Ebens, A. Search for Related Content PubMed PubMed Citation Articles by Polson, A. G. Articles by Ebens, A.

Antibody-Drug Conjugates for the Treatment of Non–Hodgkin's Lymphoma: Target and Linker-Drug Selection

Genentech, Inc., South San Francisco, California

Requests for reprints: Andrew G. Polson, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080. Phone: 650-225-5134; Fax: 650-225-6240; E-mail: polson{at}gene.com.

Key Words: Antibody-drug conjugate • CD22 • Non–Hodgkins lymphoma

Antibody-drug conjugates (ADC), potent cytotoxic drugs covalently linked to antibodies via chemical linkers, provide a means to increase the effectiveness of chemotherapy by targeting the drug to neoplastic cells while reducing side effects. Here, we systematically examine the potential targets and linker-drug combinations that could provide an optimal ADC for the treatment for non–Hodgkin's lymphoma. We identified seven antigens (CD19, CD20, CD21, CD22, CD72, CD79b, and CD180) for potential treatment of non–Hodgkin's lymphoma with ADCs. ADCs with cleavable linkers mediated in vivo efficacy via all these targets; ADCs with uncleavable linkers were only effective when targeted to CD22 and CD79b. In target-independent safety studies in rats, the uncleavable linker ADCs showed reduced toxicity, presumably due to the reduced release of free drug or other toxic metabolites into the circulation. Thus, our data suggest that ADCs with cleavable linkers work on a broad range of targets, and for specific targets, ADCs with uncleavable linkers provide a promising opportunity to improve the therapeutic window for ADCs in humans. [Cancer Res 2009;69(6):2358–64]

This article has been cited by other articles:

				A. G. Polson and M. X. Sliwkowski Toward an Effective Targeted Chemotherapy for Multiple Myeloma Clin. Cancer Res., June 15, 2009; 15(12): 3906 - 3907. [Abstract] [Full Text] [PDF]